Question-and-Answer Session
Operator
Thank you Mr. Barlow. At this time we will take calls from the audience. (Operator instructions) Your first question comes from the line of Marco Crosio [ph] with Jefferies. Please proceed.
Marco Crosio – Jefferies
Hi good morning guys its Marco Crosio in for Adam Walsh. How is everybody?
David Barlow
Hi, how are you doing Marko.
Marco Crosio, Jefferies & Company
Great, so we are expecting Phase 2’s amoebae results by the year end. Should we be looking for press release just with top line results or how do you expect to report that to us.
John Babich
Sure, this is John Babich Marco. Our expectations that we would have top line results in a press release, and that we will be looking to present the overall results or detailed results either at ACC or SNM in the early half of 2009
.
Marco Crosio, Jefferies & Company
Great and do you have any further thoughts on a Phase 3 pivotal trial design at this point or does that depend on what you see and report out for the Phase 2?
John Babich
Well certainly it’s going to be continued upon the results from this trial and also discussions with the agency.
Marco Crosio, Jefferies & Company
Finally a housekeeping question for Azedra, I didn’t quite catch, what was the MTD.
John Babich
8.0 mCi/kg in the adult population.
Marco Crosio, Jefferies & Company
Thanks for answering my questions.
John Babich
Pleasure.
Operator
And your next question comes from the line of Ken Trbovich with RBC Capital Markets. Please proceed.
Ken Trbovich – RBC Capital Markets
Thanks for taking the question. I guess the first one is really is for Dr. Coleman. You mentioned the distribution of the Trofex compounds perhaps outside of the tumor target. Can you give us a sense as to whether or not there are particular locations that make the diagnostic ability perhaps less beneficial with one of the candidates as opposed to the other for example in the bladder or other areas of the body that might obscure the prostate?
Edward Coleman
The distribution is a little bit different between the two agents. One of them has a little more liver activity, the other one of them has a little more Reno excursion than the other, but none of these are of the degree that I think that is going to cause any problems in interpreting the data. We are doing these patients with SPECT imaging, so we can differentiate the prostate gland from the bladder quite clearly.
- To read the full transcript on Seeking Alpha, click here »
